Taysha Gene Therapies (TSHA) PT Raised to $47 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Gil Blum raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $47.00 (from $45.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
